Abstract
The article presents the results of an open comparative randomized clinical study on the assessment of the reactogenicity, safety and immunogenicity of the domestic vaccine "EntseVir®" with reduced antigenic load in immunization of children aged 3 to 17 years on the schedule for 0-60 days. The vaccine is characterized by the low reactogenicity, high safety profile and immunogenicity. On main indices, it is not inferior to foreign vaccine «FSME-Immun Inject / Junior».
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
